Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) as a novel marker in T1 high-grade and T2 bladder cancer patients receiving neoadjuvant chemotherapy
about
Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer.Dual-specificity tyrosine-regulated kinase 2 is a suppressor and potential prognostic marker for liver metastasis of colorectal cancer.Downregulation of SIRT6 is associated with poor prognosis in patients with non-small cell lung cancer.Downregulation of dual-specificity tyrosine-regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin-dependent kinase 14 expression in breast cancer.Regulation of Glioma Cells Migration by DYRK2.Tumor suppressive role for kinases phosphorylating p53 in DNA damage-induced apoptosis
P2860
Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) as a novel marker in T1 high-grade and T2 bladder cancer patients receiving neoadjuvant chemotherapy
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Dual-specificity tyrosine phos ...... iving neoadjuvant chemotherapy
@ast
Dual-specificity tyrosine phos ...... iving neoadjuvant chemotherapy
@en
type
label
Dual-specificity tyrosine phos ...... iving neoadjuvant chemotherapy
@ast
Dual-specificity tyrosine phos ...... iving neoadjuvant chemotherapy
@en
prefLabel
Dual-specificity tyrosine phos ...... iving neoadjuvant chemotherapy
@ast
Dual-specificity tyrosine phos ...... iving neoadjuvant chemotherapy
@en
P2093
P2860
P1433
P1476
Dual-specificity tyrosine phos ...... iving neoadjuvant chemotherapy
@en
P2093
Akira Shimizu
Mika Terasaki
Ryo Takahashi
Ryoji Kimata
Shunichiro Nomura
Tsutomu Hamasaki
Yasuhiro Terasaki
Yasutomo Suzuki
Yukihiro Kondo
P2860
P356
10.1186/S12894-015-0040-7
P50
P577
2015-06-19T00:00:00Z